$BMSN Now that was a great read! My take is that you are correct, in that the share structure, which has been posted as unchanged as of recent times(BMSN and RGBP), acts as a bit of reassurance against an R/S, for lack of need. While the structure does provide for more dilution, there is no guarantee of that either. A previous agreement may have been similar to that occurring with convertible lenders seen aiding other companies, using a typical 4:1 model with the A/S having to expand to four times the O/S to assure that there will be enough shares available to be sold in order to return the debt owed to the lender.

So, with that out of the way, now we introduce Dr. Lander, as you already mentioned. His goal is just as you stated: to secure non-dilutive funding. Seeing he worked Wall St., he is well aware of how the share structure affects the share price, and how the share price affects company sentiment and the caliber of its potential investor base, current and future. I'm thinking Dr. Lander will secure enough non-dilutive financing to secure buyback/retirement money, thus to return upward pressure to the price per share, while simultaneously securing funds to allocate towards trials, research, and production of the therapeutic agent as well.

Upon your estimations of a fully diluted BMSN w/Hemaxellerate1 being complete with orphan designation, in command of a .04-.05 share price, one can only imagine where we could end up should there be a buyback/retirement, funding announced with no detail of usage missing, and more products being formulated, recognized and approved for use.

Once again, great post; very thought-provoking. It is my belief as well that we have a great couple of plays on our hands with the Regen Biopharma stocks. I'm looking forward to what I sense to be very bright future for the company. Thank you again!